Timothy Coughlin
Timothy Coughlin's purchase track record
Timothy Coughlin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/30/2024 | ATYR | $88K | +7.4% | +100.6% | +15.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
ADC Therapeutics Announces $86.6M Financing and Loan Amendments. ADC Therapeutics has secured $86.6 million through a private placement of 12.9 million shares at $1.42 each, along with warrants for 48.1 million shares. The company also amended its existing loan and royalty agreements. This capital raise provides additional liquidity to support operations, occurring while the stock trades near the top of its recent range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
aTyr Pharma Aligns With FDA On Phase 3 Efzofitimod Plan. aTyr Pharma announced it has reached alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to begin study-related activities in the fourth quarter of 2026. This regulatory progress follows a period where the stock traded near its 52-week low, indicating a significant step in the drug's development timeline.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| TVTX | ▲ Buy | Option Exercise | 10,000 | $265K | 6/12/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 10,000 | $501K | 6/12/2026 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 6/9/2026 | View on chart |
| VIR | ▲ Buy | Grant | 8,000 | $0 | 6/9/2026 | View on chart |
| ADCT | ▼ Sell | Tax Withholding | 12,600 | $39K | 6/3/2026 | View on chart |
| ADCT | ▲ Buy | Grant | 45,000 | $0 | 6/1/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,250 | $141K | 5/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 8,000 | $131K | 10/31/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 10,000 | $174K | 10/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 18,000 | $631K | 10/31/2025 | View on chart |
| ADCT | ▲ Buy | Grant | 40,000 | $0 | 6/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| ATYR | ▲ Buy | Open Market | 50,000 | $88K | 5/30/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| ATYR | ▼ Sell | Gift | 6,000 | $0 | 5/17/2023 | View on chart |
| ATYR | ▼ Sell | Gift | 6,000 | $0 | 5/17/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| ATYR | ▲ Buy | Option Exercise | 6,000 | — | 4/26/2023 | View on chart |
| FATE | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 1,439 | $33K | 6/3/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.